Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb - Research Grade |
---|---|
Source | CAS 1024603-92-6 |
Species | Homo sapiens |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Icrucumab,18F1,IMC-18F1,LY3012212,FLT1, VEGFR-1,anti-FLT1, VEGFR-1 |
Reference | PX-TA1257 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Icrucumab is investigated for the treatment of Colorectal Cancer.
Immobilized Human FLT1 recombinant protein (cat. No.PX-P6096) at 0.5µg/mL (100µL/well) can bind to Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb (cat. No.PX-TA1257) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
Reviews
Il n’y a pas encore d’avis.